Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 07-Jun-22 7:37 PM View:  | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 06-Jun-22 | Private Sale | 442 | $0.71 | $313.82 | (3%) 13.61K to 13.16K | |
| 07-Jun-22 7:39 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 06-Jun-22 | Private Sale | 82 | $0.71 | $58.22 | (2%) 4.26K to 4.18K | |
| 01-Apr-22 9:08 PM View: | Kellerman Donald J VP, Clinical Dev & Med Affairs | Zosano Pharma Corp (ZSAN) | 31-Mar-22 | Sale | 4,006 | $0.21 | $841.66 | (7%) 60.34K to 56.33K | |
| 01-Apr-22 9:07 PM View: | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 31-Mar-22 | Sale | 23,633 | $0.21 | $4,965.29 | (5%) 484.34K to 460.71K | |
| 01-Apr-22 9:09 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 31-Mar-22 | Sale | 8,116 | $0.21 | $1,705.17 | (5%) 154.54K to 146.43K | |
| 24-Nov-21 5:53 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 23-Nov-21 | Market Sale | 10,000 | $0.60 | $6,018.00 | (19%) 53.5K to 43.5K | < 1% |
| 19-Oct-21 9:36 PM View: | Kellerman Donald J VP, Clinical Dev & Med Affairs | Zosano Pharma Corp (ZSAN) | 15-Oct-21 | Grant | 10,000 | -- | -- | 20% 50.34K to 60.34K | |
| 19-Oct-21 9:34 PM View: | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 15-Oct-21 | Grant | 118,750 | -- | -- | 32% 365.59K to 484.34K | |
| 19-Oct-21 9:35 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 15-Oct-21 | Grant | 56,250 | -- | -- | 57% 98.29K to 154.54K | |
| 14-Jun-21 8:31 PM View: | Hagan Joseph P Director | Zosano Pharma Corp (ZSAN) | 10-Jun-21 | Grant | 15,000 | -- | -- | 200% 7.5K to 22.5K | |
| 14-Jun-21 8:36 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 10-Jun-21 | Grant | 15,000 | -- | -- | 39% 38.5K to 53.5K | |
| 14-Jun-21 8:35 PM View: | Xanthopoulos Kleanthis G Director | Zosano Pharma Corp (ZSAN) | 10-Jun-21 | Grant | 15,000 | -- | -- | 175% 8.6K to 23.6K | |
| 14-Jun-21 9:36 PM View: | Grais Linda S Director | Zosano Pharma Corp (ZSAN) | 10-Jun-21 | Grant | 15,000 | -- | -- | 200% 7.5K to 22.5K | |
| 14-Jun-21 8:38 PM View: | Elms Steve Director | Zosano Pharma Corp (ZSAN) | 10-Jun-21 | Grant | 15,000 | -- | -- | < 1% 2.73M to 2.74M | |
| 07-Jun-21 6:43 PM View: | Lewis Hayley See Remarks | Zosano Pharma Corp (ZSAN) | 04-Jun-21 | Market Sale | 1,709 | $0.81 | $1,375.74 | (3%) 51.49K to 49.78K | (2%) |
| 07-Jun-21 6:44 PM View: | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 04-Jun-21 | Market Sale | 13,158 | $0.81 | $10,592.20 | (3%) 378.75K to 365.59K | (2%) |
| 07-Jun-21 6:41 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 04-Jun-21 | Market Sale | 1,709 | $0.81 | $1,375.74 | (2%) 100.0K to 98.29K | (2%) |
| 07-Jun-21 6:42 PM View: | Kellerman Donald J VP, Clinical Dev & Med Affairs | Zosano Pharma Corp (ZSAN) | 04-Jun-21 | Market Sale | 1,709 | $0.81 | $1,375.74 | (3%) 52.05K to 50.34K | (2%) |
| 18-May-21 7:45 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 17-May-21 | Grant | 21,000 | $0.73 | $15,311.10 | 120% 17.5K to 38.5K | < 1% |
| 01-Apr-21 9:31 PM View: | Kellerman Donald J VP, Clinical Dev & Med Affairs | Zosano Pharma Corp (ZSAN) | 30-Mar-21 | Grant | 32,500 | -- | -- | 166% 19.55K to 52.05K | |
| 01-Apr-21 9:33 PM View: | Lewis Hayley See Remarks | Zosano Pharma Corp (ZSAN) | 30-Mar-21 | Grant | 32,500 | -- | -- | 171% 18.99K to 51.49K | |
| 01-Apr-21 9:33 PM View: | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 30-Mar-21 | Grant | 232,500 | -- | -- | 159% 146.25K to 378.75K | |
| 01-Apr-21 9:30 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 30-Mar-21 | Grant | 81,250 | -- | -- | 433% 18.75K to 100.0K | |
| 30-Jun-20 10:00 PM View: | Hagan Joseph P Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | 100% 0 to 7.5K | |
| 30-Jun-20 10:00 PM View: | Xanthopoulos Kleanthis G Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | 684% 1.1K to 8.6K | |
| 30-Jun-20 10:00 PM View: | Walker John Peter Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | 7% 109.01K to 116.51K | |
| 30-Jun-20 10:00 PM View: | Kellerman Donald J VP, Clinical Dev & Med Affairs | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 18,750 | -- | -- | 2356% 0.8K to 19.55K | |
| 29-Jun-20 9:56 PM View: | Grais Linda S Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | 100% 0 to 7.5K | |
| 30-Jun-20 10:00 PM View: | Lewis Hayley See Remarks | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 18,750 | -- | -- | 7878% 0.24K to 18.99K | |
| 30-Jun-20 10:00 PM View: | Lo Steven Chief Executive Officer Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 146,250 | -- | -- | 100% 0 to 146.25K | |
| 30-Jun-20 10:00 PM View: | Matthews Christine Chief Financial Officer | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 18,750 | -- | -- | 100% 0 to 18.75K | |
| 29-Jun-20 9:47 PM View: | Elms Steve Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | < 1% 2.72M to 2.73M | |
| 30-Jun-20 10:00 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 25-Jun-20 | Grant | 7,500 | -- | -- | 75% 10.0K to 17.5K | |
| 06-Dec-19 10:23 AM View: | Aisling Capital Iv, Lp 10% Owner | Zosano Pharma Corp (ZSAN) | 02-Dec-19 | Grant | 689,655 | $1.45 | $1,000,000.00 | 34% 2.03M to 2.72M | |
| 18-Apr-19 4:25 PM View: | Walker John Peter President & CEO Director | Zosano Pharma Corp (ZSAN) | 11-Apr-19 | Market Purchase | 100,000 | $3.50 | $350,000.00 | 55% 180.23K to 280.23K | (73%) |
| 12-Apr-19 4:15 PM View: | Aisling Capital Iv, Lp 10% Owner | Zosano Pharma Corp (ZSAN) | 11-Apr-19 | Grant | 428,571 | $3.50 | $1,500,000.00 | 27% 1.6M to 2.03M | (73%) |
| 28-Feb-18 5:38 PM View: | Amzak Capital Management, LLC 10% Owner | Zosano Pharma Corp (ZSAN) | 27-Feb-18 | Market Sale | 80,880 | $8.36 | $675,914.00 | (31%) 261.99K to 181.11K | 89% |
| 28-Feb-18 5:38 PM View: | Amzak Capital Management, LLC 10% Owner | Zosano Pharma Corp (ZSAN) | 27-Feb-18 | Market Sale | 5,901 | $8.26 | $48,760.00 | (3%) 181.11K to 175.21K | 89% |
| 28-Feb-18 5:38 PM View: | Amzak Capital Management, LLC 10% Owner | Zosano Pharma Corp (ZSAN) | 26-Feb-18 | Market Sale | 1,500 | $11.00 | $16,500.00 | (< 1%) 263.49K to 261.99K | 91% |
| 08-Dec-17 4:24 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 06-Dec-17 | Market Purchase | 55,000 | $0.61 | $33,407.00 | 38% 145.0K to 200.0K | (92%) |
| 04-Dec-17 4:05 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 01-Dec-17 | Market Purchase | 50,000 | $0.62 | $31,080.00 | 53% 95.0K to 145.0K | (92%) |
| 04-Dec-17 4:05 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 30-Nov-17 | Market Purchase | 45,000 | $0.62 | $27,927.00 | 90% 50.0K to 95.0K | (92%) |
| 16-Nov-17 5:28 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 15-Nov-17 | Market Purchase | 15,000 | $0.58 | $8,674.50 | 43% 35.0K to 50.0K | (92%) |
| 16-Nov-17 5:28 PM View: | Greathouse Kenneth Director | Zosano Pharma Corp (ZSAN) | 14-Nov-17 | Market Purchase | 35,000 | $0.64 | $22,484.00 | 100% 0 to 35.0K | (93%) |
| 11-Aug-17 7:18 PM View: | Walker John Peter President and CEO Director | Zosano Pharma Corp (ZSAN) | 09-Aug-17 | Disposition | 26,666 | -- | -- | (13%) 206.89K to 180.23K | |
| 25-May-17 8:45 PM View: | Walker John Peter Interim CEO Director | Zosano Pharma Corp (ZSAN) | 25-May-17 | Market Purchase | 37,550 | $1.37 | $51,338.40 | 22% 169.34K to 206.89K | (96%) |
| 25-May-17 8:55 PM View: | Erbez Georgia CFO and Chief Business Officer | Zosano Pharma Corp (ZSAN) | 25-May-17 | Market Purchase | 68,000 | $1.32 | $89,760.00 | 142% 47.75K to 115.75K | (96%) |
| 25-May-17 8:45 PM View: | Walker John Peter Interim CEO Director | Zosano Pharma Corp (ZSAN) | 24-May-17 | Market Purchase | 36,166 | $1.34 | $48,552.90 | 27% 133.18K to 169.34K | (96%) |
| 22-May-17 6:25 PM View: | Walker John Peter Interim CEO Director | Zosano Pharma Corp (ZSAN) | 18-May-17 | Grant | 60,000 | -- | -- | 82% 73.18K to 133.18K | |
| 08-May-17 6:13 PM View: | Walker John Peter Director | Zosano Pharma Corp (ZSAN) | 04-May-17 | Option Exercise | 9,478 | -- | -- | 15% 63.7K to 73.18K |
